<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2020.101005</article-id><article-id pub-id-type="publisher-id">MD-34637</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20200100000_62647998.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于SEER数据库的宫颈癌预后回顾性研究
  A Retrospective Study on the Prognosis of Cervical Cancer Based on SEER Database
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>云波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>敬</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>俊启</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>丽萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>建光</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>淄博岜山万杰医院肿瘤科，山东 淄博</addr-line></aff><aff id="aff3"><addr-line>淄博岜山万杰医院内科，山东 淄博</addr-line></aff><aff id="aff4"><addr-line>郑州大学第一附属医院放疗科，河南 郑州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>25</day><month>02</month><year>2020</year></pub-date><volume>10</volume><issue>01</issue><fpage>26</fpage><lpage>37</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨不同分期宫颈癌患者的预后及年龄、人种和婚姻状况对预后的影响。方法：搜索SEER数据库2010年~2015年病理诊断明确的宫颈癌患者，共计17,291例，除去随访不完整的患者，共15,895例。统计发病年龄和3年、5年生存率。Kaplan-Meier (K-M)法绘制生存曲线，Log-rank检验和Cox回归比较年龄、人种和婚姻对生存率的影响。结果：全部患者中位年龄为50岁，平均年龄52.02 &#177; 14.01岁。通过生存统计可见3年生存率I期 &gt; II期 &gt; III期 &gt; IV期，但在具体分期生存率IIA1 &gt; IB2 &gt; IIB &gt; IIA2，IIIB &gt; IIIA。5年生存率I期 &gt; II期 &gt; III期 &gt; IV期，但IIB &gt; IIA2、IIIB &gt; IIIA。无论是3年生存率还是5年生存率IIB期均好于IIA2期，IIIB期均好于IIIA期。从单变量分析来看在II期中白人与其他人种之间无明显差别，其余各期白人预后均好于其他人种。小于50岁患者预后均好于大于等于50岁患者，丧偶患者预后均为最差。多因素分析中人种、年龄和婚姻均有差别。结论：随着I、II、III和IV期增加总生存率下降，IIB期 &gt; IIA2期，P = 0.007，IIIB期 &gt; IIIA期，P = 0.025。人种、年龄及婚姻状况是预后独立因素。
   Objective: To explore the prognosis of different stages of cervical cancer patients and the influence of age, race and marital status on the prognosis. Methods: 17,291 cervical cancer patients with definite pathological diagnosis were searched in SEER database from 2010 to 2015. 15,895 patients were excluded from incomplete follow-up. The age of onset and 3-year and 5-year survival rates were analyzed. Kaplan-Meier (K-M) method was used to draw survival curve. Log-rank test and Cox regression were used to compare the effects of age, race and marriage on survival. Conclusion: the median age of all patients was 50 years old, with an average age of 52.02 &#177; 14.01 years. According to the 3-year survival rate, stage I &gt; stage II &gt; stage III &gt; stage IV, but in the specific stage IIA1 &gt; stage IB2 &gt; stage IIB &gt; stage IIA2, stage IIB &gt; stage IIA. The 5-year survival rate was stage I &gt; stage II &gt; stage III &gt; stage IV, but IIB &gt; IIA2, IIIB &gt; IIIA. The 3-year or 5-year survival rate of stage IIB was better than that of stage IIA2, and stage IIIB was better than that of stage IIIA. From univariate analysis, there was no significant difference between whites and other races in phase II. univariate analysis showed that the prognosis of white people was better than that of other ethnic groups, and the prognosis of patients under 50 years old was better than that of patients over 50 years old, and the prognosis of widowed patients was the worst. There were differences in race, age and marriage in multivariate analysis. Conclusion: with the increase of stage I, II, III and IV, the overall survival rate decreased. Stage IIB &gt; stage IIA2, P = 0.007, stage IIIB &gt; stage IIIA, P = 0.025. Race, age and marital status were independent prognostic factors.
 
</p></abstract><kwd-group><kwd>宫颈癌，年龄，婚姻，人种，预后, Cervical Cancer</kwd><kwd> Age</kwd><kwd> Marriage</kwd><kwd> Race</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>基于SEER数据库的宫颈癌预后回顾性研究<sup> </sup></title><p>张云波<sup>1</sup>，李敬<sup>2</sup>，刘俊启<sup>3</sup>，郑丽萍<sup>1</sup>，张建光<sup>1*</sup></p><p><sup>1</sup>淄博岜山万杰医院肿瘤科，山东 淄博</p><p><sup>2</sup>淄博岜山万杰医院内科，山东 淄博</p><p><sup>3</sup>郑州大学第一附属医院放疗科，河南 郑州</p><disp-formula id="hanspub.34637-formula74"><graphic xlink:href="//html.hanspub.org/file/5-2170228x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年2月27日；录用日期：2020年3月13日；发布日期：2020年3月20日</p><disp-formula id="hanspub.34637-formula75"><graphic xlink:href="//html.hanspub.org/file/5-2170228x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨不同分期宫颈癌患者的预后及年龄、人种和婚姻状况对预后的影响。方法：搜索SEER数据库2010年~2015年病理诊断明确的宫颈癌患者，共计17,291例，除去随访不完整的患者，共15,895例。统计发病年龄和3年、5年生存率。Kaplan-Meier (K-M)法绘制生存曲线，Log-rank检验和Cox回归比较年龄、人种和婚姻对生存率的影响。结果：全部患者中位年龄为50岁，平均年龄52.02 &#177; 14.01岁。通过生存统计可见3年生存率I期 &gt; II期 &gt; III期 &gt; IV期，但在具体分期生存率IIA1 &gt; IB2 &gt; IIB &gt; IIA2，IIIB &gt; IIIA。5年生存率I期 &gt; II期 &gt; III期 &gt; IV期，但IIB &gt; IIA2、IIIB &gt; IIIA。无论是3年生存率还是5年生存率IIB期均好于IIA2期，IIIB期均好于IIIA期。从单变量分析来看在II期中白人与其他人种之间无明显差别，其余各期白人预后均好于其他人种。小于50岁患者预后均好于大于等于50岁患者，丧偶患者预后均为最差。多因素分析中人种、年龄和婚姻均有差别。结论：随着I、II、III和IV期增加总生存率下降，IIB期 &gt; IIA2期，P = 0.007，IIIB期 &gt; IIIA期，P = 0.025。人种、年龄及婚姻状况是预后独立因素。</p><p>关键词 :宫颈癌，年龄，婚姻，人种，预后</p><disp-formula id="hanspub.34637-formula76"><graphic xlink:href="//html.hanspub.org/file/5-2170228x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-2170228x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-2170228x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>宫颈癌是女性最常见恶性肿瘤之一。根据2018年报道数据，每年大约528,000例患者被确诊为宫颈癌 [<xref ref-type="bibr" rid="hanspub.34637-ref1">1</xref>]。早期患者预后较好，晚期患者生存明显下降。本研究主要统计发病年龄及各期生存率，并分析年龄、婚姻及人种对预后影响。</p></sec><sec id="s4"><title>2. 一般资料</title><p>通过SEER*Stat软件(surveillance, epidemiology, and end result program institute SEER*Stat software)搜索SEER数据库中2010年至2015年病理诊断明确的宫颈癌患者。</p><sec id="s4_1"><title>2.1. 入选标准</title><p>1) 诊断年龄 ≥ 30岁；2) 经病理学证实为宫颈癌；3) 确诊年份为2010年~2015年。</p></sec><sec id="s4_2"><title>2.2. 排除标准</title><p>1) 病理诊断不明确；2) 诊断年龄 &lt; 30岁；3) 多原发肿瘤；4) 资料不完整患者。</p></sec><sec id="s4_3"><title>2.3. 统计学分析</title><p>应用SPSS19.0软件进行统计分析，采用Log-rank检验进行各组变量分析。采用Cox比例风险模型进行多因素分析。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 发病年龄统计</title><p>全部17,291例患者中位年龄为50岁，平均年龄52.02 &#177; 14.01岁。根据AJCC第七版分期，对15,895例分期明确患者进行分别统计。IA1期患者2146例，占13.5%，中位年龄43岁，平均年龄45.03 &#177; 11.49岁。IA2期患者569例，占3.58%，中位年龄45岁，平均年龄47.19 &#177; 11.82岁。IB1期患者3197例，占20.11%，中位年龄47岁，平均年龄49.13 &#177; 12.76岁。IB2期患者959例，占6.03%，中位年龄47岁，平均年龄50.01 &#177; 13.53岁。IIA1期患者251例，占1.58%，中位年龄58岁，平均年龄57.63 &#177; 15.40岁。IIA2期患者363例，占2.28%，中位年龄55岁，平均年龄57.06 &#177; 16.09岁。IIB期患者1634例，占10.28%，中位年龄53岁，平均年龄54.74 &#177; 13.81岁。IIIA期患者224例，占1.41%，中位年龄61岁，平均年龄61.83 &#177; 15.44岁。IIIB期患者3651例，占22.97%，中位年龄52岁，平均年龄52.70 &#177; 13.68岁。IVA期患者377例，占2.37%，中位年龄58岁，平均年龄59.04 &#177; 13.80岁。IVB期患者2524例，占15.88%，中位年龄56岁，平均年龄56.79 &#177; 13.56岁。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Age and proportion of cervical cancer in different stage</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分期</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >占比%</th><th align="center" valign="middle" >中位年龄</th><th align="center" valign="middle" >平均年龄</th></tr></thead><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IA1</td><td align="center" valign="middle" >2146</td><td align="center" valign="middle" >13.5</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >45.03 &#177; 11.49</td></tr><tr><td align="center" valign="middle" >IA2</td><td align="center" valign="middle" >569</td><td align="center" valign="middle" >3.58</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" >47.19 &#177; 11.82</td></tr><tr><td align="center" valign="middle" >IB1</td><td align="center" valign="middle" >3197</td><td align="center" valign="middle" >20.11</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >49.13 &#177; 12.76</td></tr><tr><td align="center" valign="middle" >IB2</td><td align="center" valign="middle" >959</td><td align="center" valign="middle" >6.03</td><td align="center" valign="middle" >47</td><td align="center" valign="middle" >50.01 &#177; 13.53</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IIA1</td><td align="center" valign="middle" >251</td><td align="center" valign="middle" >1.58</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >57.63 &#177; 15.40</td></tr><tr><td align="center" valign="middle" >IIA2</td><td align="center" valign="middle" >363</td><td align="center" valign="middle" >2.28</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >57.06 &#177; 16.09</td></tr><tr><td align="center" valign="middle" >IIB</td><td align="center" valign="middle" >1634</td><td align="center" valign="middle" >10.28</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >54.74 &#177; 13.81</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IIIA</td><td align="center" valign="middle" >224</td><td align="center" valign="middle" >1.41</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >61.83 &#177; 15.44</td></tr><tr><td align="center" valign="middle" >IIIB</td><td align="center" valign="middle" >3651</td><td align="center" valign="middle" >22.97</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" >52.70 &#177; 13.68</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >IVA</td><td align="center" valign="middle" >377</td><td align="center" valign="middle" >2.37</td><td align="center" valign="middle" >58</td><td align="center" valign="middle" >59.04 &#177; 13.80</td></tr><tr><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >2524</td><td align="center" valign="middle" >15.88</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >56.79 &#177; 13.56</td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >15,895</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 不同分期宫颈癌年龄情况及占比</p></sec><sec id="s5_2"><title>3.2. 婚姻状况和人种统计</title><p>对婚姻状况进行统计，已婚7217例，占41.74%。未婚4862例，占28.12%。离婚2113例，占12.22%。丧偶1619例，占9.36%。未婚同居77例，占0.45%。分居361例，占2.09%。未知1042例，占6.03%。</p><p>人种分析，白人12894例，占74.57%。黑人2400例，占13.88%。亚裔1656例，占9.58%。印第安人和阿拉斯加人196例，占1.13%。未知145，占0.84%。</p></sec><sec id="s5_3"><title>3.3. 生存率统计</title><p>对2010年和2011年5665例患者统计5年生存率为65.81%，对2010年~2013年11,252例患者统计3年生存率为71.58%。剔除分期不明确的患者后共10,286例，统计各分期生存率，见表2，图1。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Survival of cervical cancer in different stage</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分期</th><th align="center" valign="middle" >总例数</th><th align="center" valign="middle" >5年生存率%</th><th align="center" valign="middle" >3年生存率%</th></tr></thead><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >1988</td><td align="center" valign="middle" >89.43</td><td align="center" valign="middle" >91.64</td></tr><tr><td align="center" valign="middle" >IA1</td><td align="center" valign="middle" >1364</td><td align="center" valign="middle" >95.25</td><td align="center" valign="middle" >97.80</td></tr><tr><td align="center" valign="middle" >IA2</td><td align="center" valign="middle" >382</td><td align="center" valign="middle" >92.47</td><td align="center" valign="middle" >95.81</td></tr><tr><td align="center" valign="middle" >IB1</td><td align="center" valign="middle" >2102</td><td align="center" valign="middle" >89.84</td><td align="center" valign="middle" >93.58</td></tr><tr><td align="center" valign="middle" >IB2</td><td align="center" valign="middle" >624</td><td align="center" valign="middle" >76.30</td><td align="center" valign="middle" >78.21</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >1242</td><td align="center" valign="middle" >66.04</td><td align="center" valign="middle" >75.68</td></tr><tr><td align="center" valign="middle" >IIA1</td><td align="center" valign="middle" >166</td><td align="center" valign="middle" >70.00</td><td align="center" valign="middle" >79.52</td></tr><tr><td align="center" valign="middle" >IIA2</td><td align="center" valign="middle" >228</td><td align="center" valign="middle" >57.27</td><td align="center" valign="middle" >65.35</td></tr><tr><td align="center" valign="middle" >IIB</td><td align="center" valign="middle" >1076</td><td align="center" valign="middle" >65.48</td><td align="center" valign="middle" >75.09</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >2490</td><td align="center" valign="middle" >50.48</td><td align="center" valign="middle" >58.31</td></tr><tr><td align="center" valign="middle" >IIIA</td><td align="center" valign="middle" >145</td><td align="center" valign="middle" >46.05</td><td align="center" valign="middle" >51.03</td></tr><tr><td align="center" valign="middle" >IIIB</td><td align="center" valign="middle" >2345</td><td align="center" valign="middle" >50.77</td><td align="center" valign="middle" >58.76</td></tr><tr><td align="center" valign="middle" >IV</td><td align="center" valign="middle" >1854</td><td align="center" valign="middle" >18.00</td><td align="center" valign="middle" >24.11</td></tr><tr><td align="center" valign="middle" >IVA</td><td align="center" valign="middle" >244</td><td align="center" valign="middle" >23.28</td><td align="center" valign="middle" >31.15</td></tr><tr><td align="center" valign="middle" >IVB</td><td align="center" valign="middle" >1610</td><td align="center" valign="middle" >17.21</td><td align="center" valign="middle" >23.04</td></tr></tbody></table></table-wrap><p>表2. 不同分期宫颈癌生存情况</p><p>图1. 生存曲线</p></sec><sec id="s5_4"><title>3.4. 单变量分析和多因素分析</title><p>对2010~2013年11243例患者各个分期进行分析。采用Log-rank检验单变量分析，多因素分析采用Cox回归。各分期按人种、年龄和婚姻分组。人种分为白人和其他人种(黑人、亚裔、印第安人及阿拉斯加人和未知情况)。年龄分为大于等于50岁和小于50岁。婚姻分为已婚、离婚、未婚、丧偶和其他(未婚同居、分居和未知)。见表3、表4。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Variable analysis of each stag</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分期</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >I期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >人种</td><td align="center" valign="middle" >6.789</td><td align="center" valign="middle" >0.009</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >126.286</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >婚姻</td><td align="center" valign="middle" >158.425</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >II期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >人种</td><td align="center" valign="middle" >1.054</td><td align="center" valign="middle" >0.305</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >11.451</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >婚姻</td><td align="center" valign="middle" >39.123</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >III期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >人种</td><td align="center" valign="middle" >18.051</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >61.439</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >婚姻</td><td align="center" valign="middle" >75.048</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >IV期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >人种</td><td align="center" valign="middle" >4.684</td><td align="center" valign="middle" >0.03</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >13.113</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >婚姻</td><td align="center" valign="middle" >34.244</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表3. 各分期变量分析</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Multivariate analysi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >χ<sup>2</sup></th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >HR</th><th align="center" valign="middle" >95% CI</th></tr></thead><tr><td align="center" valign="middle" >人种</td><td align="center" valign="middle" >16.815</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.858</td><td align="center" valign="middle" >0.797~0.923</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >100.063</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >1.478</td><td align="center" valign="middle" >1.369~1.595</td></tr><tr><td align="center" valign="middle" >婚姻</td><td align="center" valign="middle" >124.43</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >已婚</td><td align="center" valign="middle" >14.312</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.754</td><td align="center" valign="middle" >0.651~0.872</td></tr><tr><td align="center" valign="middle" >离婚</td><td align="center" valign="middle" >118.105</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.562</td><td align="center" valign="middle" >0.506~0.623</td></tr><tr><td align="center" valign="middle" >未婚</td><td align="center" valign="middle" >19.083</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.711</td><td align="center" valign="middle" >0.629~0.805</td></tr><tr><td align="center" valign="middle" >丧偶</td><td align="center" valign="middle" >33.215</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >0.728</td><td align="center" valign="middle" >0.653~0.811</td></tr></tbody></table></table-wrap><p>表4. 多因素分析</p><p>通过生存统计可见3年生存率I期 &gt; II期 &gt; III期 &gt; IV期，但在具体分期IIA1 &gt; IB2 &gt; IIB &gt; IIA2，IIIB &gt; IIIA。5年生存率I期 &gt; II期 &gt; III期 &gt; IV期，IIB &gt; IIA2，IIIB &gt; IIIA。无论是3年生存率还是5年生存率IIA2期好于IIB期(P = 0.007)，IIIB期好于IIIA期(P = 0.025)。存在统计学差异。见图2、图3。从单变量分析来看在II期中白人与其他人种之间无明显差别，其余各期白人预后均好于其他人种。小于50岁患者预后均好于大于等于50岁患者，丧偶患者预后均为最差多因素分析中人种、年龄和婚姻均有差别。见图4~15。</p><p>图2. IIA2期和IIB期生存曲线</p><p>图3. IIIA期和IIIB期生存曲线</p><p>图4. I期患者不同人种之间比较</p><p>图5. I期患者不同年龄之间比较</p><p>图6. I期患者婚姻状况之间比较</p><p>图7. II期患者不同人种之间比较</p><p>图8. II期患者不同年龄之间比较</p><p>图9. II期患者婚姻状况之间比较</p><p>图10. III期患者不同人种之间比较</p><p>图11. III期患者不同年龄之间比较</p><p>图12. III期患者婚姻状况之间比较</p><p>图13. IV期患者人种之间比较</p><p>图14. IV期患者不同年龄之间比较</p><p>图15. IV期婚姻状况之间比较</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>宫颈癌是常见恶性肿瘤，特别是在发展中国家。早期的国外报道宫颈癌患者I~IIA期5年生存率65%以上，III期患者5年生存率只有25%~35%，IV期患者5年生存率为15%或更低 [<xref ref-type="bibr" rid="hanspub.34637-ref2">2</xref>]。张蕾等包括了138例早期(I~IIA期)宫颈癌5年生存率为78.2% [<xref ref-type="bibr" rid="hanspub.34637-ref3">3</xref>]。胡芳艳报道中晚期(II~III期)宫颈癌单纯根治性放疗和同步放化疗3年生存率分别为60%和80% [<xref ref-type="bibr" rid="hanspub.34637-ref4">4</xref>]。本研究中I期、II期、III期和IV期的5年生存率分别为89.43%、66.04%、50.48%和18%较早期国外报道数据明显提升。IIB期好于IIA2期，IIIB期好于IIIA期。IIA2中T分期定义为临床可见病灶大于4 cm，而IIB期的T分期定义为有宫旁浸润，但并没有限定病灶的大小。刘兰芳等报道认为瘤体直径 ≥ 4 cm的年轻患者淋巴结转移、深间质浸润和脉管累及均增加。也是预后较差的不良因素 [<xref ref-type="bibr" rid="hanspub.34637-ref5">5</xref>]。根据第七版AJCC分期，IIIA的T3a，而IIIB分期是T3b或T1~T3且有区域淋巴结转移。IIIB期的T分期范围较大，T1~T3之间只要出现区域淋巴结就归入IIIB期。这可能是导致IIIB期生存率好于IIIA期的原因。第八版AJCC分期对III期进行了更改，IIIA定义为T3a，IIIB定义为T3b，不再考虑区域淋巴结的情况。有报道淋巴结转移是宫颈癌独立的预后因素 [<xref ref-type="bibr" rid="hanspub.34637-ref6">6</xref>]。周滢研究认为淋巴脉管间隙浸润(lympho vacular space invasion, LVSI)与淋巴结转移关系显著，并预示着早期宫颈癌患者预后不良 [<xref ref-type="bibr" rid="hanspub.34637-ref7">7</xref>]。分析可见肿瘤病灶大小、宫旁浸润及淋巴结转移与预后密切相关。</p><p>年龄也是预后的重要因素，有研究显示年轻(35岁以下)妇女宫颈癌预后差，分子病理分析提示与survivin的表达有关 [<xref ref-type="bibr" rid="hanspub.34637-ref8">8</xref>]。黄婷等研究也认为年龄是影响宫颈癌预后的独立危险因素之一，年轻患者5年总生存率优于老年患者。Kathleen N. Moore等研究放射治疗方案调整和未完成近距离治疗患者随着年龄增加而增加，对于年龄 &gt; 50岁患者，每增加1岁会导致增加2%的死亡风险，但未发现年龄与疾病特性死亡率之间的关联 [<xref ref-type="bibr" rid="hanspub.34637-ref9">9</xref>]。也有研究认为30岁或以下患者非鳞组织、宫旁浸润、远处转移和预后差比老年宫颈癌患者更常见 [<xref ref-type="bibr" rid="hanspub.34637-ref10">10</xref>]。本研究可见各个分期中年龄小于50岁患者均优于年预后龄大于50岁的患者。在一些高收入国家的少数人群和低收入国家浸润性宫颈癌能否接受治疗对预后有重要影响。许多因素导致了宫颈癌在筛查、诊断、治疗和预后的连续过程中存在种族的差异。包括社会人口因素、获得医疗保健的机会、收入和受教育水平等因素。尽管查明了这些因素，种族的差异依然存在 [<xref ref-type="bibr" rid="hanspub.34637-ref11">11</xref>]。从SEER数据库提取(1973~2009)显示II期~IV期西班牙裔白人明显高于非西班牙裔白人 [<xref ref-type="bibr" rid="hanspub.34637-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.34637-ref13">13</xref>]。本研究中白人预后优于其他人种。宫颈癌与早婚早育多产有明确相关性。结婚年龄越早、初产年龄越小及产次越多患病比重越大 [<xref ref-type="bibr" rid="hanspub.34637-ref14">14</xref>]。有报道宫颈癌与受教育程度、居住地、结婚年龄、丈夫的伴侣数量、性交后清洗生殖器和获得卫生服务有显著相关性。每天洗澡和月经期洗澡被发现是子宫颈癌的预防因素 [<xref ref-type="bibr" rid="hanspub.34637-ref15">15</xref>]。但婚姻状况对预后的研究较少，我们发现丧偶患者的预后明显差于其他患者。</p><p>本研究中也存在局限性，对人种、年龄及婚姻状况等进行了分析，治疗方式未被纳入影响因素中。选择不同治疗方式对预后影响也是至关重要的。合理选择治疗可提高生存率。</p><p>综上所述，宫颈癌的预后受多种因素的影响。早期患者预后较好，中晚期患者预后明显下降。对存在预后不良因素的患者应当引起重视，采取更加积极的治疗。</p></sec><sec id="s7"><title>基金项目</title><p>国家重点研发计划项目(2018YFE0114100)。</p></sec><sec id="s8"><title>文章引用</title><p>张云波,李 敬,刘俊启,郑丽萍,张建光. 基于SEER数据库的宫颈癌预后回顾性研究A Retrospective Study on the Prognosis of Cervical Cancer Based on SEER Database[J]. 医学诊断, 2020, 10(01): 26-37. https://doi.org/10.12677/MD.2020.101005</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34637-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Liang, B., Li, Y. and Wang, T. (2017) A Three miRNAs Signature Predicts Survival in Cervical Cancer Using Bioinformatics Analysis. Scientific Reports, 7, Article Number: 5624.&lt;br&gt; https://doi.org/10.1038/s41598-017-06032-2</mixed-citation></ref><ref id="hanspub.34637-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Liu, T., Liu, Y., Bao, X., et a1. (2013) Overexpression of TROP2 Predicts Poor Prognosis of Patients with Cervical Cancer and Promotes the Proliferation and Invasion of Cervical Cancer Cells by Regulating ERK Signaling Pathway. PLoS One, 8, e75864.&lt;br&gt; https://doi.org/10.1371/journal.pone.0075864</mixed-citation></ref><ref id="hanspub.34637-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张蕾, 忙尼沙·阿不都拉, 胡尔西旦·尼牙孜, 等. 早期宫颈癌患者预后影响因素研究[J]. 中国全科医学, 2011, 5(14): 1517-1522.</mixed-citation></ref><ref id="hanspub.34637-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">胡芳艳. 同步放化疗治疗中晚期宫颈癌的临床效果分析[J]. 当代医学, 2018, 24(1): 115-116.</mixed-citation></ref><ref id="hanspub.34637-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">刘兰芳, 孙海燕. 831例35岁以下妇女宫颈癌的临床病例特点和预后[J]. 中国癌症杂志, 2008, 18(4): 298-301.</mixed-citation></ref><ref id="hanspub.34637-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Graves, S., Seagle, B.L.L., Strohl, A.E., et a1. (2017) Survival after Pelvic Exenteration for Cervical Cancer: A National Cancer Database Study. International Journal of Gynecologic Cancer, 27, 390-395.&lt;br&gt;https://doi.org/10.1097/IGC.0000000000000884</mixed-citation></ref><ref id="hanspub.34637-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">周滢, 姜继勇. 早期宫颈癌淋巴脉管间隙浸润与淋巴结转移的关系及其预后价值[J]. 实用妇产科杂志, 2018, 34(2): 109-112.</mixed-citation></ref><ref id="hanspub.34637-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">罗仪, 赵昌银, 王剑. 年轻宫颈癌患者预后不良的分子病理因素分析[J]. 中国综合临床, 2007, 5(23): 468-470.</mixed-citation></ref><ref id="hanspub.34637-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Moore, K.N., Java, J.J., Slaughter, K.N., et a1. (2016) Is Age a Prognostic Biomarker for Survival among Women with Locally Advanced Cervical Cancer Treated with Chemoradiation? An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis. Gynecologic Oncology, 143, 294-301.&lt;br&gt; https://doi.org/10.1016/j.ygyno.2016.08.317</mixed-citation></ref><ref id="hanspub.34637-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lau, H.-Y., Juang, C.-M., Chen, Y.-J., et a1. (2009) Aggressive Characteristics of Cervical Cancer in Young Women in Taiwan. International Journal of Gynecology &amp; Obstetrics, 107, 220-223.&lt;br&gt; https://doi.org/10.1016/j.ijgo.2009.07.029</mixed-citation></ref><ref id="hanspub.34637-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Musselwhite, L.W., Oliveira, C.M., Kwaramba, T., et a1. (2016) Racial/Ethnic Disparities in Cervical Cancer Screening and Outcomes. Acta Cytologica, 60, 518-526.&lt;br&gt; https://doi.org/10.1159/000452240</mixed-citation></ref><ref id="hanspub.34637-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, T.F. and Legg, J.S. (2014) Factors Associated with HPV Vaccine Use among Hispanic College Students. Journal of Allied Health, 43, 241-246.</mixed-citation></ref><ref id="hanspub.34637-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Eng, T.Y., Chen, T., Vincent, J., Patel, A.J., Clyburn, V. and Ha, C.S. (2017) Persistent Disparities in Hispanics with Cervical Cancer in a Major City. Journal of Racial and Ethnic Health Disparities, 4, 165-168.&lt;br&gt;https://doi.org/10.1007/s40615-016-0214-3</mixed-citation></ref><ref id="hanspub.34637-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">阔小珍, 陈惠祯. 4057例宫颈癌患者的年龄、婚育史的分析[J]. 湖北医科大学学报, 1994, 15(1): 48-49.</mixed-citation></ref><ref id="hanspub.34637-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kashyap, N., Krishnan, N., Kaur, S. and Ghai, S. (2019) Risk Factors of Cervical Cancer: A Case-Control Study. Asia-Pacific Journal of Oncology Nursing, 6, 308-314.&lt;br&gt; https://doi.org/10.4103/apjon.apjon_73_18</mixed-citation></ref></ref-list></back></article>